207 reports of this reaction
1.4% of all ENTECAVIR reports
#19 most reported adverse reaction
ALANINE AMINOTRANSFERASE INCREASED is the #19 most commonly reported adverse reaction for ENTECAVIR, manufactured by E.R. Squibb & Sons, L.L.C.. There are 207 FDA adverse event reports linking ENTECAVIR to ALANINE AMINOTRANSFERASE INCREASED. This represents approximately 1.4% of all 15,216 adverse event reports for this drug.
Patients taking ENTECAVIR who experience alanine aminotransferase increased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
ALANINE AMINOTRANSFERASE INCREASED is a less commonly reported adverse event for ENTECAVIR, but still significant enough to appear in the safety profile.
In addition to alanine aminotransferase increased, the following adverse reactions have been reported for ENTECAVIR:
The following drugs have also been linked to alanine aminotransferase increased in FDA adverse event reports:
ALANINE AMINOTRANSFERASE INCREASED has been reported as an adverse event in 207 FDA reports for ENTECAVIR. This does not prove causation, but indicates an association observed in post-market surveillance data.
ALANINE AMINOTRANSFERASE INCREASED accounts for approximately 1.4% of all adverse event reports for ENTECAVIR, making it a notable side effect.
If you experience alanine aminotransferase increased while taking ENTECAVIR, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.